AKT1 and Alzheimer disease: It improved the survival of PC12 and C6 cells, reduced the neuronal injury of hippocampal tissue and improved performance in the Morris water maze, reduced the expression of the pro-inflammatory cytokines IL-6 and TNF-α, increased the expression of the anti-inflammatory cytokine IL-10, and enhanced the activity of the PI3K/Akt signaling pathway [242], thus offering new possibilities in cannabinoid-related AD pharmacotherapy at the gene level.